BROMDAY Drug Patent Profile
✉ Email this page to a colleague
When do Bromday patents expire, and when can generic versions of Bromday launch?
Bromday is a drug marketed by Bausch And Lomb Inc and is included in one NDA.
The generic ingredient in BROMDAY is bromfenac sodium. There is one drug master file entry for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the bromfenac sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bromday
A generic version of BROMDAY was approved as bromfenac sodium by SENTISS on January 22nd, 2014.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BROMDAY?
- What are the global sales for BROMDAY?
- What is Average Wholesale Price for BROMDAY?
Summary for BROMDAY
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 42 |
| Clinical Trials: | 4 |
| Patent Applications: | 66 |
| What excipients (inactive ingredients) are in BROMDAY? | BROMDAY excipients list |
| DailyMed Link: | BROMDAY at DailyMed |
Recent Clinical Trials for BROMDAY
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Sun Pharma Global FZE | Phase 2 |
| InSite Vision | Phase 2 |
| Virdi Eye Clinic |
US Patents and Regulatory Information for BROMDAY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | BROMDAY | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 021664-002 | Oct 16, 2010 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for BROMDAY
See the table below for patents covering BROMDAY around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 80043 | ⤷ Start Trial | |
| Australia | 2878689 | ⤷ Start Trial | |
| Australia | 609932 | ⤷ Start Trial | |
| Canada | 1325382 | COMPOSITION THERAPEUTIQUE A ADMINISTRATION LOCALE POUR LES AFFECTIONS INFLAMMATOIRES (LOCALLY ADMINISTRABLE THERAPEUTIC COMPOSITION FOR INFLAMMATORY DISEASE) | ⤷ Start Trial |
| Germany | 68902649 | ⤷ Start Trial | |
| European Patent Office | 0326915 | A LOCALLY ADMINISTRABLE THERAPEUTIC COMPOSITION FOR INFLAMMATORY DISEASE | ⤷ Start Trial |
| Spain | 2052784 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for BROMDAY
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1586316 | C300494 | Netherlands | ⤷ Start Trial | PRODUCT NAME: BROMFENAC, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF HYDRAAT; REGISTRATION NO/DATE: EU/1/11/692/001 20110518 |
| 1586316 | 11C0031 | France | ⤷ Start Trial | PRODUCT NAME: BROMFENAC, SES SELS OU HYDRATES PHARMACOLOGIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/692/001 20110518 |
| 1586316 | SPC/GB11/054 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523 |
| 1586316 | 122011100019 | Germany | ⤷ Start Trial | PRODUCT NAME: BROMFENAC (2-AMINO-3-(4-BROMOBENZOYL)PHENYLESSIGSAEURE); REGISTRATION NO/DATE: EU/1/11/692/001 20110518 |
| 1586316 | 2011C/027 | Belgium | ⤷ Start Trial | PRODUCT NAME: BROMFENAC; AUTHORISATION NUMBER AND DATE: EU/1/11/692/001 20110523 |
| 1586316 | C 2011 004 | Romania | ⤷ Start Trial | PRODUCT NAME: BROMFENAC, SARURILE SI HIDRATII SAI ACCEPTABILI FARMACEUTICACID 2-[2-AMINO-3-(4-BROMOBENZOIL)FENILACETIC; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/692/001; DATE OF NATIONAL AUTHORISATION: 20110518; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/11/692/001; DATE OF FIRST AUTHORISATION IN EEA: 20110518 |
| 1586316 | 132011901975261 | Italy | ⤷ Start Trial | PRODUCT NAME: BROMFENAC(YELLOX); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/692/001, 20110518 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch